EURURO Vol. 71 No. 5
|
Platinum Opinions |
25 |
|
Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time? |
25 |
|
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert? |
27 |
|
Brief Correspondence |
29 |
|
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy |
29 |
|
The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy |
33 |
|
The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies |
37 |
|
Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older |
42 |
|
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma |
46 |
|
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma |
51 |
|
Platinum Priorities |
55 |
|
Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group |
55 |
|
Brief Correspondence |
59 |
|
Upholding Rigorous Standards: Comparable Patterns and Rates of Recurrence Between Open and Robot-assisted Radical Cystectomy |
59 |
|
Prostate Cancer |
61 |
|
Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer |
61 |
|
Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? |
70 |
|
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death |
72 |
|
The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer |
80 |
|
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes |
82 |
|
Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data |
92 |
|
Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens |
96 |
|
Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis |
98 |
|
Local Therapy for Gleason 9–10 Prostate Cancer: Looking to the Future |
106 |
|
Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response |
108 |
|
Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies? |
120 |
|
Female Urology – Incontinence |
122 |
|
Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation |
122 |
|
Bladder Endometriosis: A Rare but Challenging Condition |
140 |
|
Guidelines |
143 |
|
Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree |
143 |
|
In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane’s Legacy |
152 |
|
Surgery in Motion |
154 |
|
Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial |
154 |
|
Words of Wisdom |
163 |
|
Re: Perioperative and Short-term Outcomes of Robotic vs Open Bladder Neck Procedures for Neurogenic Incontinence |
163 |
|
Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures |
164 |
|
Re: Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial |
165 |
|
Re: The Role of Adjuvant Radiotherapy in Pathologically Lymph Node Positive Prostate Cancer |
165 |
|
Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients |
166 |
|
Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma after Nephrectomy |
167 |
|
Research Letters |
169 |
|
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? |
170 |
|
Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer |
172 |
|
Mutagenic Factors and Complex Clonal Relationship of Multifocal Urothelial Cell Carcinoma |
173 |
|
Letters to the Editor published online |
177 |
|
Re: Marco Borghesi, Hashim Ahmed, Robert Nam, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol 2017;71:353–65 |
183 |
|
Re: Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol 2017;71:195–201 |
185 |
|
Re: Omar Fahmy, Mohd Ghani Khairul-Asri, Christian Schwentner, et al. Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review. Eur Urol 2016;70:293–8 |
194 |
|
Congress Calendar |
197 |
|
Corrigenda |
200 |
|
Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65] |
200 |
|
Corrigendum re: “Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours” [Eur Urol 2017;71:213–20] |
201 |